BioMarin announced on October 27, 2025, that it is pursuing options to divest Roctavian, its gene therapy for hemophilia A, including exploring out-licensing opportunities16.
The decision to divest is aligned with BioMarin’s strategy to focus on its Enzyme Therapies and Skeletal Conditions business units, which have driven robust 2025 revenue growth1.
Roctavian is a one-time infusion therapy for adults with severe hemophilia A, currently approved and reimbursed in the U.S., Germany, and Italy46.
BioMarin cited underwhelming third quarter 2025 financial performance and adjusted its growth expectations, seeking to streamline its operations and portfolio53.
The company continues to believe Roctavian is important for the hemophilia A community and will evaluate licensing and divestment options to ensure patient access1.
BioMarin has placed its Roctavian manufacturing facility in an idle state due to sufficient existing supply, pending changes in demand or ownership4.
Sources:
1. https://www.biomarin.com/news/press-releases/biomarin-reports-third-quarter-2025-results-and-provides-corporate-update/
3. https://www.bizjournals.com/sanfrancisco/news/2025/10/28/biomarin-hemophilia-a-gene-therapy-roctavian.html
4. https://www.biomarin.com/news/press-releases/biomarin-announces-updated-strategy-for-roctavian-to-focus-on-u-s-germany-and-italy-2-2/
5. https://www.bioworld.com/articles/725577-roc-in-hard-place-biomarin-plans-divestment-to-ratchet-up-numbers
6. https://www.americanpharmaceuticalreview.com/1315-News/622365-BioMarin-Announces-Plan-to-Divest-Hemophilia-Gene-Therapy-Roctavian/